Videos

“In medicine, we're not taught the business of medicine, but the day that you become faculty at an institution or private practice, you learn that it is a business, but yet nowhere in our training are we taught that,” says Michelle Pearlman, MD.

"In many cases, we're now bringing the capabilities of the hospital into a patient's home," says Timothy D. Lyon, MD, FACS.

“There are just a lot of barriers, unfortunately, to speaking freely about women's sexual health,” says Rachel Pope, MD, MPH.

Study participants were randomly assigned to receive 6 months of HT plus local therapy or 6 months of HT alone.

“We aimed to develop a surgical decision aid to help facilitate this decision-making process for patients who are candidates for either shock wave lithotripsy or ureteroscopy with kidney stones,” says John Michael DiBianco, MD.

“Where we really need to see change is talking about what the patient wants, what they're worried about, and what would work best for them,” says Angela Fagerlin, PhD.

“I think this is a nice cluster of podcasts that really go at this from different angles,” says Stacy Loeb, MD, MSc.

"I think that it's important to have a clear understanding and articulation of what the shared goals are," says Mark S. Litwin, MD, MPH.

“Although people will look back and say, how in the world do urology and gastroenterology fit in with each other? They have everything to do with each other because we focus on the foundation,” says Michelle Pearlman, MD.

The phase 2 SALV-ENZA trial explored whether the addition of enzalutamide to salvage radiation therapy could improve outcomes in patients with high-risk, PSA-recurrent prostate cancer after radical prostatectomy.

“Effective January 1, 2023, anyone who performs a laparoscopic simple prostatectomy should be using CPT code 55867 to report that procedure,” says Jonathan Rubenstein, MD.

Combining the approved antibody-drug conjugates with other agents in this space may provide some synergy and allow even more efficacy and disease control, explains Alicia Morgans, MD.

Benjamin Lowentritt, MD, discusses how the phase 3 SPOTLIGHT trial showed the efficacy of the PSMA-PET imaging agent 18F-rhPSMA-7.3 PET across a variety of subgroups in prostate cancer.

“What's more concerning is we're seeing an increase in advanced or late-stage diagnosis, which I've seen in my practice as well,” says Derek J. Lomas, MD, PharmD.

"What came out of that meeting was looking at wellness and burnout as a preventative thing," says Diana Londoño, MD.

“We need to do better, and men in America deserve a better chance at long-term, good outcomes from their prostate cancer discovery,” says Michael S. Cookson, MD, MMHC.

"I think that to be a successful mentee, you have to view the relationship with your mentor as a 2-way street," says Mark S. Litwin, MD, MPH.

“So many patients with prostate cancer qualify for genetic testing, but it's currently underutilized,” says Stacy Loeb, MD, MSc.

"The other things that are important are to use the privilege that you have as a senior mentor, even as a mid-level or junior mentor, to help open doors for people and make connections," says Mark S. Litwin, MD, MPH.

“This study is one of the most highly anticipated of all of the metastatic hormone-sensitive setting trials that we have going on at this time,” says Alicia Morgans, MD, MPH.

“The benefits can be reaped by the vast majority of patients and because we're really undertreating these patients, we need to make a conscious effort to overcome whatever barriers are facing us,” says Alicia Morgans, MD, MPH.

"The first takeaway I would say is that there is not only a lot of passion for each of these different areas in our society, but also there's a lot of expertise and experience within our urologic community from which we can all draw upon," says Manoj Monga, MD, FACS.

“These are codes that had not been updated in decades—since they were originally written,” says Jonathan Rubenstein, MD.

“I think really identifying who's going to benefit from what combination for how long is going to be important,” says Stephanie Berg, DO.

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.

Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.

Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic prostate cancer and give his initial impression.

Several treatments are being explored across these trials, including pembrolizumab, nivolumab, enfortumab vedotin, durvalumab, avelumab, and cabozantinib.